|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
L01XX59
|
|
gptkbp:brand
|
Idhifa
|
|
gptkbp:CASNumber
|
1446502-11-9
|
|
gptkbp:developer
|
gptkb:Celgene
gptkb:Agios_Pharmaceuticals
|
|
gptkbp:hasMolecularFormula
|
C15H14N6O
|
|
gptkbp:hasSMILES
|
C1=CC(=CC=C1C2=NC3=NC=NC(=C3N2)N)C(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
enasidenib
|
|
gptkbp:KEGGID
|
gptkb:D10841
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
IDH2 inhibitor
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3544943
89683826
DB13879
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
differentiation syndrome
elevated bilirubin
|
|
gptkbp:synonym
|
AG-221
Idhifa
|
|
gptkbp:target
|
isocitrate dehydrogenase 2 (IDH2)
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
treatment of relapsed or refractory acute myeloid leukemia
|
|
gptkbp:bfsParent
|
gptkb:IDH2_gene
gptkb:R140Q_(IDH2)
gptkb:Isocitrate_dehydrogenase
gptkb:IDH2
|
|
gptkbp:bfsLayer
|
7
|